Hattori N, Nakajima M O, O'Hara K, Sawai T
Research and Development Division, Kikkoman Corporation, Chiba, Japan.
Antimicrob Agents Chemother. 1998 Jun;42(6):1406-11. doi: 10.1128/AAC.42.6.1406.
Antimicrobial susceptibility testing by the ATP-bioluminescence method has been noted for its speed; it provides susceptibility results within 2 to 5 h. However, several disagreements between the ATP method and standard methodology have been reported. The present paper describes a novel ATP method in a 3.5-h test which overcomes these deficiencies through the elimination of false-resistance discrepancies in tests on gram-negative bacteria with beta-lactam agents. In our test model using Pseudomonas aeruginosa and piperacillin, it was shown that ATP in filamentous cells accounted for the false resistance. We found that 0.5% 2-amino-2-methyl-1,3-propanediol (AMPD) extracted ATP from the filamentous cells without affecting normal cells and that 0.3 U of adenosine phosphate deaminase (APDase)/ml simultaneously digested the extracted ATP. We used the mixture of these reagents for the pretreatment of cells in a procedure we named filamentous cell treatment, prior to ATP measurements. This novel ATP method with the filamentous cell treatment eliminated false-resistance discrepancies in tests on P. aeruginosa with beta-lactam agents, including piperacillin, cefoperazone, aztreonam, imipenem-cilastatin, ceftazidime, and cefsulodin. Furthermore, this novel methodology produced results which agreed with those of the standard microdilution method in other tests on gram-negative and gram-positive bacteria, including P. aeruginosa, Escherichia coli, Staphylococcus aureus, and Enterococcus faecalis, for non-beta-lactam agents, such as fosfomycin, ofloxacin, minocycline, and aminoglycosides. MICs obtained by the novel ATP method were also in agreement with those obtained by the agar dilution method of susceptibility testing. From these results, it was shown that the novel ATP method could be used successfully to test the activities of antimicrobial agents with the elimination of the previously reported discrepancies.
ATP生物发光法进行的抗菌药敏试验因其速度快而受到关注;它能在2至5小时内提供药敏结果。然而,已有报道称ATP法与标准方法之间存在一些分歧。本文描述了一种在3.5小时测试中的新型ATP方法,该方法通过消除β-内酰胺类药物对革兰氏阴性菌测试中的假耐药差异来克服这些缺陷。在我们使用铜绿假单胞菌和哌拉西林的测试模型中,发现丝状细胞中的ATP导致了假耐药。我们发现0.5%的2-氨基-2-甲基-1,3-丙二醇(AMPD)可从丝状细胞中提取ATP而不影响正常细胞,并且0.3 U/ml的腺苷磷酸脱氨酶(APDase)可同时消化提取的ATP。在进行ATP测量之前,我们将这些试剂的混合物用于细胞预处理,这一过程我们称为丝状细胞处理。这种带有丝状细胞处理的新型ATP方法消除了β-内酰胺类药物(包括哌拉西林、头孢哌酮、氨曲南、亚胺培南-西司他丁、头孢他啶和头孢磺啶)对铜绿假单胞菌测试中的假耐药差异。此外,这种新方法在对革兰氏阴性菌和革兰氏阳性菌(包括铜绿假单胞菌、大肠杆菌、金黄色葡萄球菌和粪肠球菌)进行的其他测试中,对于非β-内酰胺类药物(如磷霉素、氧氟沙星、米诺环素和氨基糖苷类)所产生的结果与标准微量稀释法一致。通过新型ATP方法获得的最低抑菌浓度(MIC)也与琼脂稀释药敏试验获得的结果一致。从这些结果可以看出,新型ATP方法可以成功用于测试抗菌药物的活性,消除先前报道的差异。